Hanover (THG) CEO John Roche receives option and RSU awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Roche John C reported acquisition or exercise transactions in this Form 4 filing.
HANOVER INSURANCE GROUP, INC. President and CEO John C. Roche reported equity awards tied to the company’s long-term incentive plan. He received an option to buy 45,025 shares of common stock, plus stock-based awards totaling 31,229 shares at no cash cost to him.
Footnotes explain that these grants reflect performance-based restricted stock units from a 2023 award, with performance certified at 150% and 100% of target and vesting on February 27, 2026, as well as new restricted stock units and options that generally vest over three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Roche John C
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock Option (right to buy) | 45,025 | $0.00 | -- |
| Grant/Award | Common Stock | 13,254 | $0.00 | -- |
| Grant/Award | Common Stock | 8,540 | $0.00 | -- |
| Grant/Award | Common Stock | 9,435 | $0.00 | -- |
Holdings After Transaction:
Common Stock Option (right to buy) — 45,025 shares (Direct);
Common Stock — 137,103.174 shares (Direct)
Footnotes (1)
- On February 27, 2023, the Reporting Person was granted performance-based restricted stock units ("PBRSUs") pursuant to the Issuer's 2022 Long-Term Incentive Plan ("2022 LTIP"). These PBRSUs were subject to a performance-based vesting condition related to three-year average adjusted return on equity and a time-based vesting condition, and also provided for the accumulation of dividend equivalent rights. On February 24, 2026, the performance condition for this award was certified at 150% of the target award (as adjusted for accumulated dividend equivalent rights). This award remains subject to the time-based vesting condition and will vest on February 27, 2026. Does not include 14,454 shares held by the Reporting Person's spouse. On February 27, 2023, the Reporting Person was granted PBRSUs pursuant to the Issuer's 2022 LTIP. These PBRSUs were subject to a performance-based vesting condition related to three-year relative total shareholder return and a time-based vesting condition, and also provided for the accumulation of dividend equivalent rights. On February 24, 2026, the performance condition for this award was certified at 100% of the target award (as adjusted for accumulated dividend equivalent rights). This award remains subject to the time-based vesting condition and will vest on February 27, 2026. Grant of restricted stock units under the Issuer's 2022 LTIP. Such units vest on the third anniversary of the date of grant. Such options vest as to one-third of the shares on each of the first three anniversaries of the grant date.
FAQ
What insider transactions did THG President and CEO John C. Roche report?
John C. Roche reported equity awards, not open-market trades. He received options for 45,025 shares and stock-based grants totaling 31,229 common shares, all at a grant price of $0.00 per share, as part of Hanover’s long-term incentive compensation.
Were John C. Roche’s THG Form 4 transactions stock purchases or grants?
The transactions were grants and vesting-related awards, not stock purchases. The filing classifies each as an acquisition from company compensation programs, with a reported price per share of $0.00, reflecting equity incentives rather than open-market buying activity by the Hanover Insurance Group CEO.
What equity awards did THG CEO John C. Roche receive on February 24, 2026?
On February 24, 2026, Roche was granted an option for 45,025 shares and multiple common stock awards totaling 31,229 shares. These relate to performance-based and time-based restricted stock units under Hanover’s 2022 Long-Term Incentive Plan, with specified vesting schedules in the footnotes.
How are John C. Roche’s THG performance-based RSUs structured and vested?
Roche’s PBRSUs granted in 2023 carry performance conditions tied to adjusted return on equity and relative total shareholder return, plus time-based vesting. Performance was certified at 150% and 100% of target, with the resulting awards scheduled to vest on February 27, 2026, subject to continued service.
What does the THG Form 4 say about options granted to John C. Roche?
The Form 4 notes a grant of common stock options with rights to buy 45,025 THG shares. A footnote explains these options vest in three equal installments, with one-third of the shares vesting on each of the first three anniversaries of the grant date under the 2022 LTIP.